NCT00885664View on ClinicalTrials.gov

Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

September 30, 2009

Study Completion Date

March 31, 2010

Conditions
HIV Infections
Interventions
DRUG

Truvada (tenofovir/emtricitabine)

Tenofovir/emtricitabine fixed dose combination once daily

DRUG

Kaletra (lopinavir/ritonavir)

Lopinavir/ritonavir 400/100 mg twice daily

Trial Locations (1)

45267

University of Cincinnati AIDS Clinical Trials Unit, Cincinnati

Sponsors

Collaborators (2)

Abbott
Gilead Sciences
All Listed Sponsors
collaborator

Abbott

INDUSTRY

collaborator

Gilead Sciences

INDUSTRY

lead

University of Cincinnati

OTHER

NCT00885664 - Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection | Biotech Hunter | Biotech Hunter